Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Method of detection of clinically significant post-prandial hyperglycemia in normoglycemic patients

a clinically significant and postprandial hyperglycemia technology, applied in the field of clinically significant postprandial hyperglycemia in normoglycemic patients, can solve the problems of additional step, complicated and laborious mathematical calculations, etc., and achieve the effects of high risk, and low risk of occult pancreatic beta cell dysfunction

Inactive Publication Date: 2019-04-11
TRUE HEALTH IP LLC
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

This patent text describes a method for determining the health risk of a patient with pancreatic beta cell dysfunction and providing treatment guidance based on the results of various tests. The treatment guidance can include suggestions for further testing, drug therapy, lifestyle changes, and avoidance of certain medications. The method can also involve the use of antioxidants, anti-coagulants, anti-dyslipidemics, and other agents to treat the condition. Overall, the patent text presents a detailed approach for assessing and treating patients with pancreatic beta cell dysfunction.

Problems solved by technology

Most OGTTs and CLIX scoring require a patient to remain in the doctor's office for 2 hours post dose, and most clinicians only test baseline samples and the 2-hour time point, and not the labor-intensive 3-5 additional times blood draws during the 2-hour period necessary for CLIX scoring, due to labor and cost constraints.
Additionally, complicated and laborious mathematical calculations need to be performed in order to optimize detection of at-risk individuals with these techniques, and kidney function (approximated by blood creatinine levels / eGFR) needs to be accounted for, causing an additional step.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method of detection of clinically significant post-prandial hyperglycemia in normoglycemic patients
  • Method of detection of clinically significant post-prandial hyperglycemia in normoglycemic patients
  • Method of detection of clinically significant post-prandial hyperglycemia in normoglycemic patients

Examples

Experimental program
Comparison scheme
Effect test

examples

[0097]Study No. 1

[0098]A study was done wherein 100 patients were sampled at baseline (fasting) and again at 30 minutes, 1 hour, 90 minutes, and 2 hours post glucose load in an OGTT. Analytes listed in FIGS. 1-4 were measured. For each figure, glycemic status of the each patient was categorized into NGT, IFG, IGT, and COI according to standard guidelines issued by the American Diabetes Association (see DIABETES CARE, vol. 20, sup. 7, Jul. 1997). The figures then show whether the 1 hour glucose was above or below 155 mg / dL, which is the cutoff value established in the literature as a post-prandial hyperglycemic excursion value associated with increased risk of diabetes and resulting cardio-diabetic complications; this 1 hour cutoff value is further associated with decreased first phase insulin secretion response due to occult beta cell dysfunction in NOT individuals (see Abdul-Ghani and DeFronzo, DIABETES CARE, vol. 32, sup. 2, Nov. 2009). CLIX scores were calculated based on the mea...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

This invention relates to a method for detecting the presence of or likelihood of a patient of developing occult pancreatic beta cell dysfunction, and a method for detecting the presence of or likelihood of a patient of developing clinically significant post-prandial hyperglycemia. The methods involve (a) measuring a level of alpha-hydroxybutyrate (AHB) in a single fasting baseline biological sample of the patient; (b) comparing the level of AHB in the single fasting baseline biological sample to a reference AHB level; and (c) determining the presence of or likelihood of developing the disorder in the patient based on the comparison in step (b). An increased AHB level at fasting baseline indicates that a normoglycemic, normo-insulinemic and / or non-dyslipidemic patient has developed or has an increased likelihood of developing occult pancreatic beta cell dysfunction. An increased AHB level at fasting baseline and an elevated glucose level of at least about 155 mg / dL at 30 minutes and / or 1 hour indicates that a normoglycemic, normo-insulinemic and / or non-dyslipidemic patient has developed or has an increased likelihood of developing clinically significant post-prandial hyperglycemia.

Description

[0001]PRIORITY CLAIM[0002]This application is a continuation of U.S. patent application Ser. No. 14 / 154,074 filed Jan. 13, 2014 which claims priority to U.S. Provisional Application No. 61 / 751,328, filed Jan. 11, 2013, U.S. Provisional Application No. 61 / 831,337, filed Jun. 5, 2013, and U.S. Provisional Application No. 61 / 831,405, filed Jun. 5, 2013, the entirety of each of which are incorporated herein by reference and relied upon.BACKGROUND[0003]Currently a number of tests exist that can diagnose patients as diabetic or pre-diabetic, including pre-diabetic conditions, such as occult pancreatic beta cell dysfunction or post-prandial hyperglycemia. Such tests include glucose, insulin, pro-insulin, c-peptide, HbA1c, fructosamine, glycation gap, 1,5-anhydroglucitol (1,5-AG), OGTT, CLIX scoring, HOMA IR scoring, and IRI scores based on combinations of AHB, L-GPC, and Oleic Acid weighted by insulin or BMI. Used alone or in combination some of these tests can detect the presence of Type ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): G01N33/50G01N33/92G01N33/68
CPCG01N2800/044G01N33/92G01N2800/042G01N2800/50G01N33/6893G01N33/50
Inventor VARVEL, STEVECAFFREY, REBECCA E.POTTALA, JAMES V.
Owner TRUE HEALTH IP LLC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products